
ELTX Stock Forecast & Price Target
ELTX Analyst Ratings
Bulls say
Elicio Therapeutics is expected to see continued success and growth in the coming years with its innovative immunotherapies targeting KRAS-mutated cancers. The company's impressive leadership, promising pipeline, and potential market size make it a strong contender in the competitive biotechnology industry. However, careful evaluation of clinical trial data and the ever-evolving nature of oncology treatments should be considered when making investment decisions.
Bears say
Elicio Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies for the treatment of cancer, with a focus on mKRAS-positive pancreatic cancer, CRC, lung cancer, and other mKRAS-positive cancers. While their proprietary AMP technology has shown some early promise in terms of biomarker reduction and immune response, the company is still in the early stages of clinical development and the Phase 2 trial design raises some concerns. Additionally, their market opportunity seems limited, as there are already approved targeted therapies for mKRAS-positive cancers.
This aggregate rating is based on analysts' research of Elicio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ELTX Analyst Forecast & Price Prediction
Start investing in ELTX
Order type
Buy in
Order amount
Est. shares
0 shares